Ranibizumab
- Generic Name
- Ranibizumab
- Brand Names
- Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 347396-82-1
- Unique Ingredient Identifier
- ZL1R02VT79
- Background
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...
- Indication
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...
- Associated Conditions
- Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD
- Conditions
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 388
- Registration Number
- NCT04740671
- Locations
- 🇸🇰
Fakultna Nemocnica S Poliklinikou Nove Zamky Oftalmologicke Nelozkove Oddelenie, Nové Zámky, Slovakia
🇪🇸Instituto Oftalmologico Fernandez-Vega, Oviedo, Spain
🇺🇸Associated Retina Consultants-Gilbert, Gilbert, Arizona, United States
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 494
- Registration Number
- NCT04662944
- Locations
- 🇪🇸
Novartis Investigative Site, Leon, Spain
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
- Conditions
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 442
- Registration Number
- NCT04657289
- Locations
- 🇦🇷
Centro Oftalmológico Dr. Charles S.A., Capital Federal, Argentina
🇦🇷Oftalmos, Capital Federal, Argentina
🇦🇷Grupo Laser Vision, Rosario, Argentina
Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 251
- Registration Number
- NCT04567303
- Locations
- 🇺🇸
The Retina Care Center, Baltimore, Maryland, United States
🇺🇸Mid Atlantic Retina - Wills Eye Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Tennessee Retina PC., Nashville, Tennessee, United States
Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2020-07-09
- Target Recruit Count
- 142
- Registration Number
- NCT04464694
- Locations
- 🇨🇳
Eye & Ent Hospital of Fudan University, Shanghai, China
🇨🇳Ningbo Eye Hospital, Ningbo, Zhejiang, China
🇨🇳Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China
Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 100
- Registration Number
- NCT04460001
- Locations
- 🇪🇬
Wael, Asyut, Egypt
Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Far Eastern Memorial Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT04089605
- Locations
- 🇨🇳
Far Eastern Memorial Hospital, New Taipei, Taiwan
Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Minia University
- Target Recruit Count
- 400
- Registration Number
- NCT04087746
- Locations
- 🇪🇬
Minia University, Minya, Egypt
Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Wake Forest University Health Sciences
- Registration Number
- NCT04075136
- Locations
- 🇺🇸
Wake Forest Health Sciences, Winston-Salem, North Carolina, United States
Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion
- Conditions
- Interventions
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 100
- Registration Number
- NCT04062370
- Locations
- 🇨🇳
Chuangxin Huang, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.